Displaying drugs 1701 - 1725 of 2098 in total
Evening primrose oil
Evening primrose oil comes from the extraction from Oenothera biennis seeds and it is commonly used as an alternative source for omega-6 essential fatty acids. In its composition it presents some fatty acids such as DB00132 and DB13854. Evening primrose oil has been filled for the FDA by Humanetics Corporation...
Investigational
Nutraceutical
Matched Mixtures name: … OGAMIX(Evening primrose oil 500 mg, Lecithin oil 500 mg, Fish oil 125 mgand Vitamin E 10 mg Soft Gelatin …
Matched Products: … Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA) ... Nn EVENING PRIMROSE OIL 500MG (with 10% GLA) …
Matched Products: … Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA) ... Nn EVENING PRIMROSE OIL 500MG (with 10% GLA) …
Poloxamer 331
Investigational
ISIS 104838
ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).
Investigational
2,2-Dimethylbutyrate
Investigational
INKP-102
INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
Investigational
ISS-1018
ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC)....
Investigational
INO-1001
Investigational
PPI-1019
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
ORE-1001
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Investigational
NCX-1000
NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).
Investigational
DRF-1042
Investigational
G100
Investigational
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
TSHA-104
Investigational
IBIO-100
IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.
Investigational
TSHA-101
Investigational
MDX-1097
MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Investigational
TSHA-102
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
AOC-1020
AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational
ADX-10061
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
ONCOS‐102
Investigational
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
BN104
Investigational
Displaying drugs 1701 - 1725 of 2098 in total